Arndt Rolfs steps aside as Cen­to­gene CEO, with An­drin Os­wald named as his suc­ces­sor; João Sif­fert lands an­oth­er CEO post at De­sign Ther­a­peu­tics

Arndt Rolfs

→ There’s a change at the top at Ger­man rare dis­ease biotech Cen­to­gene. Arndt Rolfs de­cid­ed to step down as CEO, ef­fec­tive Tues­day, and Big Phar­ma vet An­drin Os­wald will re­place him start­ing Dec. 1. Os­wald, the del­e­gate for Covid-19 vac­cines and im­munother­a­pies for the fed­er­al gov­ern­ment of Switzer­land, re­cent­ly spent 4 years with the Bill & Melin­da Gates Foun­da­tion as di­rec­tor of life sci­ence in­dus­try en­gage­ment and part­ner­ships. He was al­so a busi­ness in­te­gra­tion ex­ec at GSK and di­vi­sion head of vac­cines & di­ag­nos­tics at No­var­tis.

Rolfs will stay as an ad­vi­sor dur­ing the tran­si­tion. Cen­to­gene and Evotec an­nounced an ex­pan­sion of their part­ner­ship in Au­gust that tar­gets Gauch­er dis­ease, the most com­mon lyso­so­mal stor­age dis­or­der.

João Sif­fert

→ Not even a month af­ter ex­it­ing stage left from a tee­ter­ing Abeona Ther­a­peu­tics, João Sif­fert is now at the helm of San Diego start­up De­sign Ther­a­peu­tics, which launched with a $43 mil­lion round in March and is geared to­ward de­gen­er­a­tive dis­eases brought about by nu­cleotide re­peat ex­pan­sions. Sif­fert, who was al­so Abeona’s head of R&D and CMO, was the head­lin­er in a mass ex­o­dus at the gene ther­a­py biotech that in­clud­ed 5 board mem­bers. Sif­fert will al­so be a board mem­ber at De­sign Ther­a­peu­tics, which was co-found­ed by Pratik Shah and Aseem Ansari and has a lead pro­gram that tar­gets Friedre­ich’s atax­ia.

→ In the process of de­vel­op­ing pro­grams for pem­phi­gus vul­garis and celi­ac dis­ease, Ger­man biotech Topas Ther­a­peu­tics has tapped Klaus Mar­tin as CEO, a tran­si­tion that ac­tu­al­ly took place in Au­gust af­ter the res­ig­na­tion of Timm Jessen but was re­leased nonethe­less this week. Mar­tin was pres­i­dent of Toron­to-based Apo­bi­ologix the last 2 years be­fore mak­ing the move to Topas. Among his oth­er stops, he was al­so CSO of Pol­phar­ma Bi­o­log­ics and led busi­ness de­vel­op­ment & li­cens­ing and port­fo­lio man­age­ment dur­ing his 8 years at San­doz.

→ Two new C-suite ex­ecs are on board at Vac­citech, the Ox­ford T cell vac­cine and im­munother­a­py play­er co-found­ed by Sarah Gilbert, with Meg Mar­shall com­ing on as CMO and Geor­gy Egorov as CFO. Mar­shall has con­sult­ed at Vac­citech since June and has held clin­i­cal re­search di­rec­tor­ships at Pfiz­er, Kite and Ky­owa Kirin. Egorov bounces to Vac­citech from Ex­sci­en­tia, an AI drug dis­cov­ery com­pa­ny al­so based in Ox­ford, spend­ing 2 years as their CFO and as a board mem­ber.

Chris­tine Heenan

Noubar Afeyan’s Flag­ship Pi­o­neer­ing has brought Chris­tine Heenan on board as se­nior part­ner and chief com­mu­ni­ca­tions of­fi­cer. A for­mer speech­writer and se­nior pol­i­cy an­a­lyst in the Clin­ton ad­min­is­tra­tion, Heenan found­ed and is pres­i­dent of the Claren­don Group, which has ad­vised the Broad In­sti­tute, the Bill and Melin­da Gates Foun­da­tion and Har­vard. Heenan has con­nec­tions to Har­vard, serv­ing as the uni­ver­si­ty’s VP of pub­lic af­fairs and com­mu­ni­ca­tions from 2008-15.

→ Af­ter David Main took the helm as pres­i­dent and CEO in Ju­ly, two more ex­ecs have joined Toron­to biotech Notch Ther­a­peu­tics, fo­cused on cre­at­ing al­lo­gene­ic T cell ther­a­pies from re­new­able stem cell sources. EVP, fi­nance and CFO Kam­ran Alam was in­ter­im CFO at In­ter­leukin Ther­a­peu­tics for a time af­ter the com­pa­ny merged with Aquinox Phar­ma­ceu­ti­cals, where he was an 8-year vet. Gre­go­ry Block, who steps in as SVP, cor­po­rate de­vel­op­ment, had just com­plet­ed a year-and-a-half run at Astel­las as their di­rec­tor of busi­ness de­vel­op­ment.

Mah­boob Rah­man

Mah­boob Rah­man, well-trav­eled in Big Phar­ma, has been in­stalled as CSO of Cy­to­Dyn, which hit a snag in Ju­ly to the tune of a refuse-to-file let­ter for its lead drug leron­limab in HIV. The drug is al­so in a Phase II tri­al for graft-ver­sus-host dis­ease and a Phase Ib/II tri­al for metasta­t­ic triple-neg­a­tive breast can­cer. An alum of Cen­to­cor/J&J, Pfiz­er and No­var­tis, Rah­man spent the last year as Mesoblast’s glob­al head of im­munol­o­gy de­vel­op­ment and phar­ma­covig­i­lance. He was al­so pres­i­dent and CMO at Glen­mark be­fore he made his way to Mesoblast.

Third Rock-backed Rheos Med­i­cines — fo­cused on the field of im­munome­tab­o­lism — has picked up Da­nia Rabah as CSO. Rabah hails from Bio­gen, where she served as head of drug dis­cov­ery in­cu­ba­tor, re­search and ear­ly de­vel­op­ment.

→ Cam­bridge, MA mi­cro­bio­me play­er Seres Ther­a­peu­tics con­tin­ues to fill out its lead­er­ship team, with David Ege join­ing as chief tech­nol­o­gy of­fi­cer and Jayne Gansler as chief peo­ple of­fi­cer. In April, Lisa von Moltke was named CMO of Seres, which mount­ed a Phase III come­back in the sum­mer for their C. dif­fi­cile pro­gram SER-109 af­ter a crush­ing Phase II fail. Ege held a va­ri­ety of posts at Mer­ck since 2003, ex­it­ing as the glob­al lead for dig­i­tal strat­e­gy in the phar­ma gi­ant’s man­u­fac­tur­ing di­vi­sion. A J&J and Gen­zyme vet, Gansler leaps to Seres from Ari­ad Phar­ma­ceu­ti­cals, where she was SVP, head of hu­man re­sources.

Behrad De­r­akhshan

Michael Car­ruthers and Behrad De­r­akhshan have head­ed to mus­cu­loskele­tal dis­ease-fo­cused Edge­wise Ther­a­peu­tics as CFO and CBO, re­spec­tive­ly, three months af­ter the Boul­der, CO biotech made an­oth­er C-suite move by bring­ing in CMO Kirsten Gruis. Edge­wise’s lead can­di­date, EDG-5506 for Duchenne and Beck­er mus­cu­lar dy­s­tro­phy, is in clin­i­cal de­vel­op­ment. Car­ruthers was CFO at 2 oth­er Boul­der com­pa­nies, Ar­ray Bio­Phar­ma and Ni­valis Ther­a­peu­tics, where he was al­so in­ter­im pres­i­dent. De­r­akhshan, an Alex­ion vet, was most re­cent­ly CBO at Vec­tivBio and led busi­ness de­vel­op­ment at Ther­a­chon from 2017-19.

→ Fo­cused on sep­sis-as­so­ci­at­ed acute kid­ney in­jury and in the midst of a Phase III piv­otal clin­i­cal tri­al, Dutch biotech AM-Phar­ma has wel­comed Maarten Kraan as CMO and Te­un van de Laar as VP, man­u­fac­tur­ing and sup­ply chain man­age­ment. Kraan has been around the R&D block with Bris­tol My­ers Squibb, Roche and As­traZeneca, pri­mar­i­ly in in­flam­ma­to­ry dis­eases, and most re­cent­ly led R&D at French phar­ma Pierre Fab­re Phar­ma­ceu­ti­cals. A 10-year vet of Mer­ck, van de Laar moves on to AM-Phar­ma from his post at Aduro Biotech as VP, CMC tech­ni­cal op­er­a­tions.

George El­dridge

Co-found­ed by Bob Langer and fo­cused on oral sus­tained-re­lease ther­a­pies, Wa­ter­town, MA-based Lyn­dra Ther­a­peu­tics has named George El­dridge as their CFO. El­dridge has been a CFO at a bushel of biotechs in the past, in­clud­ing Pro­teon Ther­a­peu­tics (his pre­vi­ous gig), Tar­gan­ta Ther­a­peu­tics and The­ri­on Bi­o­log­ics. This marks the third se­nior man­age­ment po­si­tion to be filled at Lyn­dra since Feb­ru­ary, with El­dridge join­ing chief tech­nol­o­gy of­fi­cer Örn Al­mars­son and CMO Richard Scran­ton.

→ Char­lottesville, VA-based Dif­fu­sion Phar­ma­ceu­ti­cals, look­ing to treat dis­eases where hy­pox­ia plays a big role, has re­cruit­ed Chris Gal­loway as CMO. A for­mer med­ical af­fairs di­rec­tor in Mer­ck’s im­munother­a­py di­vi­sion, Gal­loway has spent the last 2 years as se­nior med­ical di­rec­tor in crit­i­cal care for San Diego biotech La Jol­la Phar­ma­ceu­ti­cal.

David Ja­cobs

→ Swiss top­i­cal eye drug de­vel­op­er Oculis SA has brought on David Ja­cobs as chief de­vel­op­ment of­fi­cer of its US of­fice, where Sylvia Che­ung was ap­point­ed CFO last month. Ja­cobs had been VP, clin­i­cal de­vel­op­ment and med­ical af­fairs at Os­mot­i­ca Phar­ma­ceu­ti­cals for the last 3 years and held drug de­vel­op­ment roles at J&J, Dai­ichi Sankyo, Ap­tal­is Phar­ma­ceu­ti­cals and King Phar­ma­ceu­ti­cals.

Mereo Bio­Phar­ma has made a cou­ple of new per­son­nel moves with Chris­tine Fox as CFO and Hei­di Pe­tersen as SVP, reg­u­la­to­ry af­fairs. Start­ing in Jan­u­ary 2021, Fox will re­place in­ter­im CFO Michael Wyz­ga, who will stay on as a board mem­ber. A KP­MG vet, Fox had been group fi­nan­cial con­troller and trea­sur­er for Trav­el­port. Pe­tersen, who starts Nov. 2, has been in reg­u­la­to­ry af­fairs for 25 years and jumps over to Mereo from Kar­tos Ther­a­peu­tics. She’s al­so been a reg­u­la­to­ry ex­ec at Phar­ma­cylics and Im­mune De­sign, which was scooped up by Mer­ck in March 2019.

→ Af­ter rak­ing in $28.5 mil­lion to dive in­to Phase II ear­li­er this month, Sen­sei Bio­ther­a­peu­tics has named Anu Hoey as CBO. Hoey joins the com­pa­ny af­ter hav­ing served in roles at Sec­ond Genome, In­ven­ra, Ar­cus Bio­sciences and Sutro Bio­phar­ma.

→ While de­vel­op­ing the first blood-based test of ear­ly on­set Alzheimer’s dis­ease, Di­a­dem has plucked up Paul Kin­non as CEO. Paul jumps to the helm with stints at Pre­dic­tIm­mune, Transge­nom­ic, ZyGem and Life Tech­nolo­gies (now Ther­mo Fish­er) among oth­ers un­der his belt.

Sam Whit­ing

Sam Whit­ing has breezed in­to Ver­sant-backed South San Fran­cis­co on­col­o­gy play­er Tem­pest Ther­a­peu­tics, which is de­vel­op­ing their small mol­e­cule pipeline to treat tu­mors, as EVP and CMO. Whit­ing, who was in clin­i­cal re­search ear­ly in his ca­reer at Fred Hutch, was with Calithera since 2016 and had been their SVP of clin­i­cal de­vel­op­ment pri­or to his ar­rival at Tem­pest.

→ Speak­ing of Ver­sant-backed biotechs, neu­rore­gen­er­a­tion start­up Pipeline Ther­a­peu­tics has hand­ed the CFO reins to Pe­ter Slover. He’s an alum of 2 oth­er biotechs in the San Diego area — at Sophiris Bio, where he was their CFO since 2013, and be­fore that at Anadys Phar­ma­ceu­ti­cals, where he was VP, fi­nance and op­er­a­tions among sev­er­al man­age­ment roles dur­ing his 8 years.

Erin Cowhig

Erin Cowhig has been named as the first chief peo­ple of­fi­cer of Cam­bridge, MA drug dis­cov­ery pi­o­neer Nim­bus Ther­a­peu­tics, which chose 4 new tar­gets for its pipeline in June. Cowhig has left Ver­tex, where she had 2 sep­a­rate tenures in hu­man re­sources. Sand­wiched in be­tween, Cowhig was se­nior di­rec­tor, tal­ent ac­qui­si­tion and tal­ent man­age­ment at Agios.

→ Ef­fec­tive last Fri­day, Jen­nifer Chien has stepped aside as chief com­mer­cial of­fi­cer of Pitts­burgh-based Krys­tal Biotech “to pur­sue an­oth­er op­por­tu­ni­ty.” A group of mem­bers from the com­mer­cial team will fill in while the search gets un­der­way for her re­place­ment. Chien is a Sanofi alum who joined Krys­tal in Jan­u­ary.

Moya Daniels

→ San Diego re­gen­er­a­tive med­i­cine de­vel­op­er His­to­gen has se­lect­ed Moya Daniels as EVP and head of reg­u­la­to­ry, qual­i­ty and clin­i­cal op­er­a­tions. Daniels makes the move af­ter be­ing SVP of GMP qual­i­ty at San­Bio. She’s al­so held po­si­tions in reg­u­la­to­ry af­fairs and qual­i­ty as­sur­ance at Or­chard Ther­a­peu­tics, Fate Ther­a­peu­tics and Osiris Ther­a­peu­tics.

David Crist has been ap­point­ed VP of sales at Boston-based Aveo On­col­o­gy, whose NDA sub­mis­sion for tivozanib — a vas­cu­lar en­dothe­lial growth fac­tor re­cep­tor ty­ro­sine ki­nase in­hibitor (VEG­FR-TKI) to treat re­lapsed or re­frac­to­ry re­nal cell car­ci­no­ma — was ac­cept­ed for fil­ing in June af­ter re­peat­ed re­buffs and is now un­der re­view with an ac­tion date of March 31, 2021. Pri­or to Aveo, Crist was gen­er­al man­ag­er of hema­tol­ogy on­col­o­gy US fran­chise at ar­genx.

Hol­ly Vance

→ Seat­tle-based Ne­oleukin Ther­a­peu­tics, whose lead can­di­date NL-201 is a de no­vo IL-2/IL-15 ag­o­nist for can­cer, has named Hol­ly Vance their gen­er­al coun­sel. Vance was pre­vi­ous­ly as­so­ciate gen­er­al coun­sel for the Bill and Melin­da Gates Foun­da­tion, lend­ing guid­ance to the foun­da­tion’s Strate­gic In­vest­ment Fund.

Phar­maEssen­tia has tapped Ray­mond Ur­ban­s­ki as head of clin­i­cal de­vel­op­ment and med­ical af­fairs for its US sub­sidiary. Ur­ban­s­ki hops aboard af­ter stints at GT Bio­phar­ma — as CMO and pres­i­dent — Mannkind and My­lan.

Matthew Pat­ter­son is lend­ing a hand on the board of di­rec­tors to both PureTech Health — which late last month was gun­ning for a Nas­daq de­but — and on­col­o­gy play­er Vor Bio­phar­ma. Pat­ter­son is strate­gic ad­vi­sor to Au­dentes, the com­pa­ny he co-found­ed and helmed un­til the Astel­las ac­qui­si­tion closed in Jan­u­ary.

Mark Cor­ri­g­an

→ Af­ter bring­ing in Bud Brigham as a board mem­ber last month, Austin im­muno-on­col­o­gy com­pa­ny Perseus Hold­ings has giv­en Mark Cor­ri­g­an a seat at the board of di­rec­tors. Cor­ri­g­an was re­cent­ly CEO of Cor­re­vio and pres­i­dent of R&D at Tremeau Phar­ma­ceu­ti­cals.

→ Dig­i­tal health com­pa­ny Ar­i­ana Phar­ma has brought on Kia Mote­sharei to its board of di­rec­tors. Cur­rent­ly, Morte­sharei serves as SVP of busi­ness de­vel­op­ment & cor­po­rate strat­e­gy with Akcea Ther­a­peu­tics. In the past, he held roles at Mer­ck KGaA, Dyax, Gen­fit and Ac­tivX.

→ De­vel­op­ing ther­a­pies to re­pair dam­aged tis­sues, Pitts­burgh-based Noveome Ther­a­peu­tics has cho­sen Michelle Berrey and An­na­maria Kausz to be on the board of di­rec­tors. Berrey, the ex-CEO of Chimerix, is now a sci­en­tif­ic ad­vi­sor for Vi­iV/GSK. Kausz has been CMO at Al­lena Phar­ma­ceu­ti­cals since 2015.

Gi­na Con­syl­man

John McHutchi­son-led As­sem­bly Bio­sciences, which part­nered on its hep B drugs with BeiGene in Ju­ly, has made Gi­na Con­syl­man a mem­ber of their board of di­rec­tors. A Bio­gen and Ve­rastem vet, Con­syl­man is Iron­wood Phar­ma­ceu­ti­cals’ SVP and CFO.

Gilead-part­nered Vi­en­na-based im­munother­a­py com­pa­ny Hookipa has made the ad­di­tion of Jean-Charles So­ria to its board of di­rec­tors. So­ria is a pro­fes­sor of med­i­cine and med­ical on­col­o­gy at the Uni­ver­si­ty of Paris-Saclay and cur­rent­ly serves as di­rec­tor gen­er­al of the Gus­tave Roussy Can­cer Cen­ter.

Gre­go­ry Berk has been added to the board of di­rec­tors at can­cer-fo­cused In­flec­tion Bio­sciences out of Dublin. Berk is a long­time CMO at such biotechs as Vedantra Phar­ma­ceu­ti­cals, Ve­rastem and Sideris Phar­ma­ceu­ti­cals.

Tanya Lewis

→ On­colyt­ic im­munother­a­py de­vel­op­er Replimune out of Woburn, MA, has ap­point­ed Tanya Lewis to the board of di­rec­tors. Lewis, a long­time reg­u­la­to­ry ex­ec, is Karyopharm’s EVP, chief reg­u­la­to­ry strat­e­gy and strate­gic op­er­a­tions.

Bi­cy­cle Ther­a­peu­tics has in­creased the mem­ber­ship in their sci­en­tif­ic ad­vi­so­ry board. It now in­cludes Uni­ver­si­ty of Penn­syl­va­nia pro­fes­sor Gar­ret FitzGer­ald, Ar­se­nal­Bio CSO Jane Gro­gan, Can­cer Re­search UK chief clin­i­cian Charles Swan­ton and Cae­tano Reis e Sousa of the Crick In­sti­tute.

The Big Phar­ma dis­card pile; Lay­offs all around while some biotechs bid farewell; New Roche CEO as­sem­bles top team; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

With earnings seasons in full swing, we’ve listened in on all the calls so you don’t have to. But news is popping up from all corners, so make sure you check out our other updates, too.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Sen. Ron Wyden (D-OR) (Francis Chung/E&E News/Politico via AP Images)

In­fla­tion re­bates in­com­ing: Wyden calls on CMS to move quick­ly as No­var­tis CEO pledges re­ver­sal

Senate Finance Chair Ron Wyden (D-OR) this week sent a letter to the head of the Centers for Medicare & Medicaid Services seeking an update on how and when new inflation-linked rebates will take effect for drugs that see major price spikes.

The newly signed Inflation Reduction Act requires manufacturers to pay a rebate to Medicare when they increase drug prices faster than the rate of inflation.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Af­ter 13 years, Ramy Mah­moud steps in­to CEO seat at Opti­nose; Ru­pert Vessey set to ex­it Bris­tol My­ers in Ju­ly

After 13 years as president and COO at Optinose, Ramy Mahmoud has stepped into a new role as its CEO. He is taking the place of Peter Miller, who stepped down earlier this week, though Miller is still staying with the company as a consultant.

In 2010, the two business partners joined Optinose to take it in a new direction, transforming it from a delivery platform to product company. They previously worked together at Johnson & Johnson, when Miller was president at Janssen and Mahmoud headed medical affairs. Miller said after he learned about Optinose, “I did what I always do, which is find people smarter than me to talk with about the idea. And the first person I called was Ramy … and I said, ‘Hey, Ramy, what do you think of this technology?’”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Trodelvy notch­es a win in most com­mon form of breast can­cer

Following a promise last year to go “big and fast in breast cancer,” Gilead has secured a win for Trodelvy in the most common form.

The drug was approved to treat HR-positive, HER2-negative breast cancer patients who’ve already received endocrine-based therapy and at least two other systemic therapies for metastatic cancer, Gilead announced on Friday.

Trodelvy won its first indication in metastatic triple-negative breast cancer back in 2020, and has since added urothelial cancer to the list. HR-positive HER2-negative breast cancer accounts for roughly 70% of new breast cancer cases worldwide per year, according to senior VP of oncology clinical development Bill Grossman, and many patients develop resistance to endocrine-based therapies or worsen on chemotherapy.

Raymond Stevens, Structure Therapeutics CEO

Be­hind Fri­day's $161M IPO: A star sci­en­tist, GPCR drug dis­cov­ery and a plan to chal­lenge phar­ma in di­a­betes

What does it take to pull off a $161 million biotech IPO these days?

In Structure Therapeutics’ case, it means having a star scientist co-founder paired with the computational drug discovery company Schrödinger, $198 million in private funding from blue-chip investors, almost six years of research work on G protein-coupled receptors and a slate of oral, small-molecule drugs, with an eye on the huge and growing diabetes and weight-loss market.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Te­va drops out of in­dus­try trade group PhRMA

Following in AbbVie’s footsteps, Teva confirmed on Friday that it’s dropping out of the industry trade group Pharmaceutical Research and Manufacturers of America (PhRMA).

Teva didn’t give a reason for its decision to leave, saying only in a statement to Endpoints News that it annually reviews “effectiveness and value of engagements, consultants and memberships to ensure our investments are properly seated.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.

Sanofi CFO Jean-Baptiste de Chatillon (L) and CEO Paul Hudson (Romuald Meigneux/Sipa via AP Images)

Sanofi sees downtick in flu sales as it preps for launch of RSV an­ti­body

Sanofi expects its RSV antibody jointly developed with AstraZeneca will be available next season, executive VP of vaccines Thomas Triomphe announced on the company’s quarterly call.

Beyfortus, also known as nirsevimab, was approved in the EU back in November and is currently under FDA review with an expected decision coming in the third quarter of this year. The news comes as the FDA plans to hold advisory committee meetings over the next couple months to review RSV vaccines from Pfizer and GSK.

Christophe Weber, Takeda CEO (Photographer: Shoko Takayasu/Bloomberg via Getty Images)

Take­da fo­cus­es on ‘di­verse’ pipeline prospects on heels of two ac­qui­si­tions

After a whopping $4 billion asset buy from Nimbus Therapeutics, along with a $400 million deal with Hutchmed for a colorectal cancer drug, Takeda executives touted pipeline optimism on its latest earnings call this week.

That’s because the TYK2 inhibitor for psoriasis Takeda is getting from Nimbus, along with the Hutchmed fruquintinib commercialization outside of China, are just two of what it reports are 10 late-stage development programs of promising candidates.

Regeneron CSO George Yancopoulos (L) and CEO Len Schleifer at a groundbreaking for its new Tarrytown, NY facility, June 2022 (Lev Radin/Pacific Press/LightRocket via Getty Images)

In show­down with Roche, Re­gen­eron gears up for po­ten­tial Eylea ex­pan­sion amid Covid de­cline

Regeneron faced a substantial slump in overall revenue last year, but the focus still remains on some of its biggest blockbusters.

The pharma with several high-profile partnerships — Sanofi and Bayer among them — said Friday that Q4 revenue was down 31% for the quarter, and down 24% for the entire year. However, that won’t stop blockbuster expansion plans.

One of those is Eylea, the Bayer-partnered eye disease drug that has been in major competition with Roche’s Vabysmo. While Eylea is currently only approved in a 2 mg dose, the company recently filed for approval to give a 8 mg dose, in hopes of making a longer-lasting treatment.